Meet Your 2022 OTS Trainee Reps
Speaker: Chantal Ferguson, MD, PhD Candidate and Hassan Fakih, PhD Date: February 24, 2022 Time: 11-12 EST Description: The OTS values and encourages the contribution of trainees to the society. The trainee representative to the Board of Directors position was created to give trainees [...]
A Potent ASO Shows Encouraging Results in A Single-Patient Pilot Study for ALS
Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease in which motor neurons die. Since the motor neurons that die control voluntary muscles, the disease causes great difficulty for those who must live with it. They will experience loss of motor control of the [...]
A Perspective From Industry – A Conversation With Richard S. Geary, Ph.D. Executive Vice President, Chief Development Officer at Ionis Pharmaceuticals
Speaker: Richard S. Geary, Ph.D. Date: February 10, 2022 Time: 11-12 EST Description: The OTS Webinar series is pleased to feature Dr. Richard Geary, the current President Elect, and the Executive Vice President, Chief Development Officer at Ionis Pharmaceuticals. For part of the webinar [...]
Interview with Punit Seth, PhD
Punit Seth, PhD SVP Research, Alnylam Pharmaceuticals How did you become interested in the field of oligonucleotides? It was serendipity. I was hired 21 years back as an organic chemist at Ibis Therapeutics, a division of Isis Pharmaceuticals, to target structured RNA with [...]
Does CRISPR Gene Editing Increase the Risk of Developing Cancer?
CRISPR is a useful tool in a wide array of applications, and one of the most headline-grabbing is its potential in gene editing. As with any new technology or medication, there are inherent risks that must be discovered and mitigated. This is especially true [...]
A Conversation with OTS President, Prof. David Corey
Speaker: David Corey, Ph.D. Date: January 13, 2022 Time: 11-12 EST Description: Join us for an open discussion on the future of the OTS. Prof. David Corey will share his vision for, and answer questions about the OTS. Hosted by former trainee reps, Ronald [...]
Clinical Trials Begin for Ultra-Rare Treatment of Alexander Disease
It is always exciting to observe phenomenal results in the treatment of a disease in animal studies, and even more so to see them move into clinical trials. ASOs have proven to be efficient at providing deep reductions in disease causing proteins, and a [...]
Looking back… Looking forward
This will be my last contribution that I write as President of our Society. On January 1st, 2022, I will become ‘Immediate Past-President’. David Corey (University of Texas, Southwestern) will take over as President and Richard Geary (Ionis Pharmaceuticals) will become the Society’s next [...]
Can an ASO Reduce Disease Progression in ALS?
What if you noticed your body acting a bit “off,” doing something unusual and more than a bit worrying? Then, you go to a doctor and are eventually told that you have a debilitating neurodegenerative disease and can expect to progressively lose control of [...]
Interview with Vasant Jadhav, PhD.
Vasant Jadhav, PhD. SVP Head of RNAi Platform Alnylam Pharmaceuticals How did you become interested in the field of oligonucleotides and who were your early mentors? During undergrad, I was intrigued by the molecular machines and mechanisms behind secrets of life- replication, transcription, [...]